October 2026

---

Jeevan Therapeutics is advancing a first-in-class bispecific nanobody designed to address two complementary, validated biological pathways involved in Crohn’s disease persistence and relapse. Despite significant advances in treatment, many people living with Crohn’s disease still do not achieve durable disease control. Current and emerging therapies generally suppress an inflammatory pathway or address one part of the disease biology.

We believe a different approach is needed.

Addressing Two Complementary Pathways

Our lead program is designed to simultaneously limit the migration of pathogenic immune cells into the gut and block interactions of tissue-resident cells associated with persistent disease.

By addressing these complementary mechanisms with a single therapeutic, our goal is to achieve deeper and more durable disease control without broad immune suppression.

We are developing the program using a bispecific nanobody format, providing a compact and modular therapeutic architecture well suited to dual targeting.

Building the Crohn’s Program

Over the past year, Jeevan has continued to advance the scientific and development strategy for our lead program.

We have filed three provisional patent applications covering our bispecific nanobody program and underlying target-specific approaches, establishing a foundation for continued intellectual property development.

Jeevan has successfully produced its next-generation bispecific nanobody constructs, marking an important transition from discovery and engineering into the functional characterization of candidate therapeutics. These constructs are now advancing through evaluation and optimization to support lead selection, with in vivo proof-of-concept as the next major development milestone.

Our work remains focused on translating validated Crohn’s biology into a differentiated therapeutic approach with the potential to meaningfully change how the disease is treated.

Focused Today. Building for Tomorrow

Crohn’s is our lead indication and where we’ve built the development strategy.